Use of Biperiden for the Prevention of Post-traumatic Epilepsy
Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study
Sponsor: Federal University of São Paulo
Terminated
Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.
Other terminated trials from Federal University of São Paulo
Other Traumatic Brain Injury trials with similar outcome
A PHASE3 clinical study on Traumatic Brain Injury, this trial is terminated or withdrawn. The trial is conducted by Federal University of São Paulo and has accumulated 12 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2021 — Feb 2023 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Apr 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Federal University of São Paulo
- University of Sao Paulo
For direct contact, visit the study record on ClinicalTrials.gov .